Prior authorization denied: appeal by drug
Each drug has its own clinical criteria, common denial reasons, and the documentation that overturns the denial. Pick yours.
Wegovy (semaglutide)
GLP-1 for weight management
Zepbound (tirzepatide)
GIP/GLP-1 for weight management
Ozempic (semaglutide)
GLP-1 for type 2 diabetes
Mounjaro (tirzepatide)
GIP/GLP-1 for type 2 diabetes
Saxenda (liraglutide)
GLP-1 for weight management
Humira (adalimumab)
TNF inhibitor
Stelara (ustekinumab)
IL-12/23 inhibitor
Enbrel (etanercept)
TNF inhibitor
Dupixent (dupilumab)
IL-4/13 inhibitor
Skyrizi (risankizumab)
IL-23 inhibitor
Trikafta (elexacaftor/tezacaftor/ivacaftor)
CFTR modulator
Eliquis (apixaban)
DOAC anticoagulant
Jardiance (empagliflozin)
SGLT2 inhibitor
Vyvanse (lisdexamfetamine)
Stimulant for ADHD or BED
Empaveli (pegcetacoplan)
Complement inhibitor for PNH
Upload your PA denial for a free analysis
The free read identifies what your insurer requires, what evidence is missing, and whether a step-therapy override applies.
Not legal or medical advice. This page is a self-help resource. You make your own decisions. Strip personal identifiers (name, date of birth, address, member ID) from any document before uploading or sharing. The information here summarizes commonly-published payer policies and federal rules; confirm against your specific plan document and the current denial letter before acting.